Exclusive Summary

• Lansoprazole, a widely prescribed first-line Proton Pump Inhibitor (PPI), targets over a billion patients globally with GERD and H. pylori infections, representing a massive, constant, and essential therapeutic demand.
• The presentation of 30 mg * 7/14 tablets per carton perfectly aligns with the standard 1-to-2 week clinical treatment regimens outlined in global gastrointestinal guidelines, enhancing patient compliance and streamlining pharmacy dispensing.
• With the originator patent long expired, this product capitalizes on China's highly integrated API-to-finished-formulation robust supply chain to deliver compelling cost advantages, empowering overseas distributors to secure lucrative margins in both public tenders and retail networks.